Approved source synthesisEvidence current through August 2026

Retatrutide Full Evidence Review

September 01, 2026 · 4 minutes

Retatrutide has a well-defined molecular and receptor-pharmacology record, substantial randomized evidence for weight and glycemic endpoints, and a large ongoing clinical program. Evidence strength differs sharply by question: the Phase 2 obesity and diabetes reports and TRANSCEND-T2D-1 are peer reviewed, while most available TRIUMPH outcome information at the cutoff was conference or sponsor-topline material.

Evidence boundary: This review concerns Lilly's investigated LY3437943 and the exact materials used in cited studies. It does not establish equivalence for another material sold under the retatrutide name.

Technical conclusion

Trial and dataset accounting

The evidence dossier reconciles 33 prospective interventional studies and treats each participant dataset once. Registry entries, conference presentations, sponsor releases, substudies, stored-sample analyses, and later publications remain linked to their parent trial. P014, P023–P030

The Phase 2 liver-fat and body-composition publications are prespecified substudies of the obesity and diabetes trials, respectively. They add measurement detail without creating independent replications. P004–P007

Phase 3 status

TRANSCEND-T2D-1 was the only peer-reviewed Phase 3 result identified by the cutoff. TRIUMPH design and estimand methods were peer reviewed, but the principal reported outcomes for TRIUMPH-1 through -4 remained conference or sponsor disclosures. P008–P014

Comparison and outcomes boundaries

Numerical comparisons with semaglutide or tirzepatide trials are cross-trial observations, not head-to-head evidence. Cardiovascular risk-factor or biomarker changes are not cardiovascular-event outcomes. Comparator outcome trials remain context only. P019–P022, P026, P029

Safety and product identity

Gastrointestinal intolerance and increased heart rate recur across reported datasets. Rare, long-latency, reproductive, and complete Phase 3 safety questions require longer and more complete reporting. P003–P005, P008, P010–P013

The small third-party vial series documented content disagreement in three consumer-submitted samples. It supports product-specific analytical caution but neither estimates market prevalence nor proves equivalence to Lilly's clinical material. P016–P018

Study map

Study records discussed

Identity, discovery, and analytical recordsSee approved evidence mapCompleted

Cell Metabolism

RET-STUDY-P002

Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. 2022. DOI: 10.1016/j.cmet.2022.07.013. PMID: 35985340. NCT03841630. https://www.cell.com/cell-metabolism/